3-V Biosciences Finds $20M In Funding

Menlo Park-based 3-V Biosciences, which is developing treatments for Hepatitus C (HCV), said this week that it has closed a preferred round of funding, worht a minimum of $20M. The round came from Kleiner Perkins Caufield & Byers and New Enterprise Associates, both current investors in the firm. 3-V Biosciences is headed by Merdad V. Parsey. More information »